IL152227A0 - Daily treatment for erectile dysfunction using a pdes inhibitor - Google Patents

Daily treatment for erectile dysfunction using a pdes inhibitor

Info

Publication number
IL152227A0
IL152227A0 IL15222701A IL15222701A IL152227A0 IL 152227 A0 IL152227 A0 IL 152227A0 IL 15222701 A IL15222701 A IL 15222701A IL 15222701 A IL15222701 A IL 15222701A IL 152227 A0 IL152227 A0 IL 152227A0
Authority
IL
Israel
Prior art keywords
erectile dysfunction
daily treatment
pdes inhibitor
pdes
inhibitor
Prior art date
Application number
IL15222701A
Other languages
English (en)
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of IL152227A0 publication Critical patent/IL152227A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL15222701A 2000-04-26 2001-04-13 Daily treatment for erectile dysfunction using a pdes inhibitor IL152227A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/558,911 US6451807B1 (en) 1999-04-30 2000-04-26 Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
PCT/US2001/012512 WO2001080860A2 (fr) 2000-04-26 2001-04-13 Traitement quotidien de la dyserection utilisant un inhibiteur de pde5

Publications (1)

Publication Number Publication Date
IL152227A0 true IL152227A0 (en) 2003-05-29

Family

ID=24231497

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15222701A IL152227A0 (en) 2000-04-26 2001-04-13 Daily treatment for erectile dysfunction using a pdes inhibitor

Country Status (20)

Country Link
US (2) US6451807B1 (fr)
EP (1) EP1276481A2 (fr)
JP (1) JP2003531174A (fr)
KR (1) KR20030007551A (fr)
CN (1) CN1446091A (fr)
AU (1) AU2001253612A1 (fr)
BR (1) BR0110373A (fr)
CA (1) CA2407519A1 (fr)
CZ (1) CZ20023577A3 (fr)
EA (1) EA200201011A1 (fr)
HR (1) HRP20020827A2 (fr)
HU (1) HUP0300477A3 (fr)
IL (1) IL152227A0 (fr)
MX (1) MXPA02010539A (fr)
NO (1) NO20025138L (fr)
NZ (1) NZ521869A (fr)
PL (1) PL360186A1 (fr)
SK (1) SK15392002A3 (fr)
WO (1) WO2001080860A2 (fr)
ZA (1) ZA200208776B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
IL135817A0 (en) * 1999-04-30 2001-05-20 Lilly Icos Llc Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles
CA2406947A1 (fr) * 2000-04-19 2001-10-25 Johns Hopkins University Procedes de prevention et de traitement des troubles gastro-intestinaux
US8133903B2 (en) * 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
AU2005277384B2 (en) * 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7265248B1 (en) 2005-04-29 2007-09-04 Technology Innovations, Llc Compositions and methods for the treatment of malaria
WO2007100387A2 (fr) * 2005-11-03 2007-09-07 Dr. Reddy's Laboratories Ltd. Procédé de préparation de tadalafil
CA2661483A1 (fr) * 2006-08-24 2008-02-28 Surface Logix, Inc. Composes de pharmacocinetique amelioree
TWI462923B (zh) * 2010-10-18 2014-12-01 Univ Kaohsiung Medical Ｋｍｕｐ－３之心肌梗塞疾患用途
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
JP6578046B1 (ja) * 2018-08-23 2019-09-18 Ｔｏｗａ Ｃｏｒｐｏｒａｔｉｏｎ 株式会社 Ｐｄｅ５阻害用医薬組成物及びｐｄｅ５阻害用食品組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931445A (en) 1988-10-06 1990-06-05 Irwin Goldstein Agents for treatment of male impotence
NZ234186A (en) 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
EP1038963B1 (fr) 1993-05-27 2009-08-05 Board Of Regents Of The University Of Washington Phosphodiésterase de fixation du monophosphate de guanosine cyclique et avec specificité pour celui-ci et procédé d'obtention
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
YU49898A (sh) 1996-05-10 2000-03-21 Icos Corporation Hemijska jedinjenja
AU1025899A (en) 1998-09-16 2000-04-03 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors

Also Published As

Publication number Publication date
CA2407519A1 (fr) 2001-11-01
NO20025138D0 (no) 2002-10-25
CZ20023577A3 (cs) 2003-06-18
US20030100478A1 (en) 2003-05-29
HUP0300477A3 (en) 2004-10-28
ZA200208776B (en) 2003-06-03
EP1276481A2 (fr) 2003-01-22
KR20030007551A (ko) 2003-01-23
BR0110373A (pt) 2003-02-18
NO20025138L (no) 2002-12-16
MXPA02010539A (es) 2003-05-14
EA200201011A1 (ru) 2003-06-26
AU2001253612A1 (en) 2001-11-07
HUP0300477A2 (hu) 2003-06-28
CN1446091A (zh) 2003-10-01
WO2001080860A2 (fr) 2001-11-01
JP2003531174A (ja) 2003-10-21
WO2001080860A3 (fr) 2002-06-06
NZ521869A (en) 2004-10-29
US6451807B1 (en) 2002-09-17
HRP20020827A2 (en) 2004-12-31
SK15392002A3 (sk) 2003-03-04
PL360186A1 (en) 2004-09-06

Similar Documents

Publication Publication Date Title
IL153492A0 (en) Treatment of male sexual dysfunction
HUP0102834A3 (en) Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
IL213240A0 (en) Method of treatment using lighnd-immunogen conjugates
IL152227A0 (en) Daily treatment for erectile dysfunction using a pdes inhibitor
EP1337255A4 (fr) Utilisation d'inhibiteurs p38 pour le traitement de toux inflammatoire
EP1448194A4 (fr) Forme posologique contenant de l'apomorphine pour l'amelioration de la dyserection male
EP1294411A4 (fr) Nouveau traitement contre la toux
PL362462A1 (en) Apparatus for lipolysis for aesthetic treatment
IL154642A0 (en) Treatment of urinary dysfunction
IL152658A0 (en) Mmp-2/mmp-9 inhibitors
IL154215A0 (en) Medicine for fighting against sexual dysfunction
AU2002246924A8 (en) Treatment of erectile dysfunction with rho-kinase inhibitors
IL155775A0 (en) Treatment of male sexual dysfunction
PL362980A1 (en) Treatment of sexual dysfunction
EP1223957A4 (fr) Procede servant a traiter le dysfonctionnement erectile
AU2000275972A1 (en) Pde iii inhibitors for treating sexual dysfunction
EP1267911A4 (fr) Methode de traitement
GB2364078B (en) Ground treatment
AU1079402A (en) Wastewater treatment
GB0025655D0 (en) Sludge treatment
AU2929401A (en) Treatment of shoulder dysfunction using a percutaneous intramuscular stimulationsystem
GB0016693D0 (en) Cough treatment
GB0004751D0 (en) Waste treatment
AU3713201A (en) A method of treatment
ZA991676B (en) A device for use in the treatment of erectile dysfunction.